Galectin Therapeutics (GALT) Shares are Down -58.61%

Galectin Therapeutics (GALT) : During the past 4 weeks, traders have been relatively bearish on Galectin Therapeutics (GALT), hence the stock is down -33.17% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -58.68% relative to the S&P 500. The 4-week change in the price of the stock is -33.53% and the stock has fallen -58.61% in the past 1 week.

The stock has recorded a 20-day Moving Average of 40.51% and the 50-Day Moving Average is 39.1%.The 200 Day SMA reached 26.86%


Galectin Therapeutics (NASDAQ:GALT): The stock opened in the green at $1.23 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.23 and a low of $1.1 for the day. The stock did not find buyers even at the lows and closed at $1.13 recording a loss of -7.38%. 1,632,130 shares exchanged hands during the trading day. The stock had closed at $1.13 in the previous days trading.

Galectin Therapeutics (GALT) : Currently there are 3 street experts covering Galectin Therapeutics (GALT) stock. The most bullish and bearish price target for the stock is $12 and $1 respectively for the short term. The average price target of all the analysts comes to $4.75. The estimated standard deviation from the target is $6.29.

Galectin Therapeutics Inc. is a biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The companys drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two compounds in development GRMD02 and GMCT01 both of which have shown promise in preclinical studies in treatment of fibrosis and in cancer therapy. The Company is focusing on the development of GRMD02 intended to be used in the treatment of liver fibrosis and fatty liver disease and in cancer therapy in combination with immunesystem modifying agent(s).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *